Abstract: The present invention relates to a formulation of Ivermectin in soft capsules. In particular, the present invention relates to a formulation of Ivermectin in soft capsules which allows proper absorption in water, allowing the drug to be consumed at any time. Ivermectin, as an insoluble active ingredient, according to the invention, can be formulated in a liquid solution without compromising its stability and without creating impurities to form a suitable soft gelatin capsule. Therefore, the invention comprises a formulation comprising Ivermectin in a lipid medium which includes a surfactant in combination with an oily solvent, a co-surfactant and an oxidant, to form a soft capsule comprising a collagen coating, a plasticiser and gelatin. The field of the invention relates to improving the bioavailability of insoluble drugs such as Ivermectin for delivery in oral soft gelatin capsule forms.

Abstract: The present invention provides a pharmaceutical formulation suitable for filling softgel capsules comprising: (a) a therapeutically effective amount of a non-steroidal anti-inflammatory drug selected from the group consisting of selected from the group consisting of (1) the propionic acid derivatives; (2) the acetic acid derivatives; (3) the fenamic acid derivatives; (4) the biphenylcarboxylic acid derivatives; and (5) the oxicams; as well as Cox 2 inhibitors and mixtures thereof; and (b) a solvent system comprising 40% to 60% by weight a polyoxyethylene ether of the formula: 1

Abstract: The present invention provides a pharmaceutical formulation suitable for filling softgel capsules comprising: (a) a therapeutically effective amount of a non-steroidal anti-inflammatory drug selected from the group consisting of selected from the group consisting of (1) the propionic acid derivatives; (2) the acetic acid derivatives; (3) the fenamic acid derivatives; (4) the biphenylcarboxylic acid derivatives; and (5) the oxicams; as well as Cox 2 inhibitors and mixtures thereof; and (b) a solvent system comprising 40% to 60% by weight a polyoxyethylene ether of the formula: wherein n=1 to 6; 15% to 35% by weight of glycerin and 15% to 35% by weight water. In the case of compositions containing an NSAID having carboxyl function an alkaline hydroxide may be added to neutralize said hydroxide function.

Abstract: The present invention provides a pharmaceutical formulation suitable for filling softgel capsules comprising: (a) a therapeutically effective amount of a non-steroidal anti-inflammatory drug selected from the group consisting of selected from the group consisting of (1) the propionic acid derivatives; (2) the acetic acid derivatives; (3) the fenamic acid derivatives; (4) the biphenylcarboxylic acid derivatives; and (5) the oxicams; as well as Cox 2 inhibitors and mixtures thereof; and (b) a solvent system comprising 40% to 60% by weight a polyoxyethylene ether of the formula: 1